IBC Advanced Technologies is launching its subsidiary, RadSep, which will be dedicated to radiochemical separation technology for the radiopharmaceutical industry.
RadSep's proprietary Molecular Recognition Technology (MRT) introduces an approach to separating upstream radioisotopes used in the production of feedstocks, as well as downstream radioisotopes used directly in the manufacture of drug products for radioligand therapies.
The company said that when the MRT is embedded in a production process, including in a Current Good Manufacturing Practice environment, it allows for selective, single-step separation of critical radioisotopes. This benefits the supply chain and eases shortages caused by suboptimal separation processes, such as ion exchange resins, IBC highlighted. It added that the MRT can be used in the industrial setting to conserve and recycle radioisotopes such as radium-226.
IBC launched its MRT flowsheets in 2023 to equip producers of actinium-225 and lead-212 to streamline and improve their production processes and recycling recovery rates of target radioisotopes.
